Want to see SE:ACTI full AI Analyst Report?
ACTI Stock Chart & Stats
kr0.04
<kr0.01(1.97%)
At close: 4:00 PM EST
kr0.04
<kr0.01(1.97%)
Day’s Range― - ―
52-Week Rangekr3.46 - kr12.90
Previous CloseN/A
Volume903.68K
Average Volume (3M)46.69K
Market Cap
kr91.08M
Enterprise Valuekr106.98M
Total Cash (Recent Filing)kr43.90M
Total Debt (Recent Filing)kr100.00K
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding26,360,670
10 Day Avg. Volume59,653
30 Day Avg. Volume46,694
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)111.47
Price to Sales (P/S)0.00
P/FCF Ratio-191.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr21.50M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageDebt is now almost eliminated, reducing interest and refinancing pressure while preserving financial flexibility for clinical development. This is a durable balance-sheet advantage, although it does not by itself solve the company’s need to fund operations.
Narrowing LossesNet losses have narrowed materially from roughly -58.7M in 2022 to -37.3M in 2025 and -33.6M in TTM. Continued improvement could extend the company’s runway and improve operating efficiency, even though profitability remains unachieved.
Improving Cash BurnOperating cash flow improved from -54.9M in 2022 to -31.4M in TTM, indicating that cash consumption is moderating. If sustained, this trend could reduce funding pressure over the next several quarters, although cash flow remains negative.
Bears Say
No Reported RevenueZero revenue across all reported periods means the company has not yet demonstrated commercial monetization of its pipeline. Without recurring sales or partner income evidenced here, its ability to scale and fund development internally remains structurally limited.
Persistent Cash ConsumptionOperating and free cash flow remain consistently negative, so the business is consuming cash rather than self-funding operations. Persistent burn can require additional financing and may constrain the pace of clinical development if improvement does not continue.
Declining Equity And Negative ReturnsEquity fell from 55.6M in 2025 to 37.2M in TTM, while returns on equity were strongly negative in every period. This points to ongoing value erosion and potential dilution risk if losses continue to require external funding.
Active Biotech AB News
ACTI FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was kr3.46 and its highest was kr12.90 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is kr91.08M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is Nov 05, 2026 which is in 23 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Aug 20, 2026. The company reported -kr0.383 earnings per share for the quarter.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 26,360,670 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -kr0.383 in its last earnings report. Following the earnings report the stock price went up 2.713%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in SE:ACTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Oncopeptides AB
―
SynAct Pharma AB
―
Cantargia AB
―